ClinicalTrials.gg
CompletedNCT04773782Updated Jan 13, 2026

A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

A Phase 1/2 interventional study of avapritinib in Solid Tumor, Unspecified, Child, Relapsed Solid Neoplasm and CNS Tumor, sponsored by Blueprint Medicines Corporation. Completed at 26 sites in 9 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Blueprint Medicines Corporation (part of Sanofi) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
29
Allocation
Not applicable
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Central Nervous System Neoplasms with a site in United States — 46 open to participants now, 74 under way, 3 of them phase 3. Central Nervous System Neoplasms · United States.

Enrollment
214th of 399
29 · median 31
Started
2022
with 13 others
Phase 1/2
70 of 547
7 open now
Registered
492nd of 547
by date

Among the 547 studies in Central Nervous System Neoplasms with a site in United States, this one is the 214th largest by enrollment of the 399 interventional ones that give a count, is one of 14 that started in 2022, is one of 70 in phase 1/2, and was the 492nd registered.

Central Nervous System Neoplasms

699 studies on the registry are indexed under Central Nervous System Neoplasms; 66 are open to participants now.

Browse Central Nervous System Neoplasms studies →

Open to participants now

46 of the 547 studies in Central Nervous System Neoplasms with a site in United States are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 57 Central Nervous System Neoplasms studies recruiting now, 35 (61%) set no upper age limit and 19 (33%) stop at 75 or younger; 35 take children under 18; 6 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Central Nervous System Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1/2, multicenter, open-label trial of avapritinib in participants 2 to \< 18 years of age with advanced relapsed/refractory (R/R) solid tumors, including central nervous system (CNS) tumors, that harbor a PDGFRA and/or KIT mutation (including non-synonymous point mutations, insertions, and deletions) or amplification, or DMG-H3K27a who have no available curative treatment options. This is a single-arm trial in which all participants will receive avapritinib. The study consists of 2 parts: dose confirmation, safety, and PK (Part 1) and initial efficacy, safety, and PK at the Part 2 recommended dose (Part 2).

03

Conditions studied

  • Solid Tumor, Unspecified, Child
  • Relapsed Solid Neoplasm
  • CNS Tumor

Keywords

  • KIT
  • PDGFRA
  • Relapsed/Refractory Solid Tumor
  • Glioma
  • H3K27M
  • DMG-H3K27a
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be 2 to \< 18 years of age at the time of signing the .
  2. Diagnosis

    1. Participant has confirmed diagnosis of R/R solid tumor, including CNS tumors, with a mutation (including non-synonymous point mutations, insertions, and deletions) in PDGFRA and/or KIT (confirmed by local mutational testing of tumor sample) that has progressed despite standard therapy and no alternative treatment option is available. Participant with R/R solid tumors with only PDGFRA and/or KIT amplifications may be included with approval from the Sponsor.

      OR

    2. Participant has confirmed diagnosis of DMG-H3K27a (confirmed by local testing of tumor sample) that has failed standard therapy or for which no standard therapy that may convey clinical benefit exists, as judged by the investigator.
  3. Participants with CNS disease should be on a stable (≤ 10% change) or decreasing dose of for at least 7 days prior to first dose of avapritinib, with no plans for dose escalation.
  4. Disease extent: a. Part 1: All participants must have at least 1 as defined by v1.1 or Response Assessment in Neuro-Oncology (RANO) (for CNS tumors). If radiation therapy has been administered, at least 1 measurable lesion must not have been irradiated, or must have clearly progressed since being irradiated as per RANO and must be ≥ 12 weeks from radiation to any target lesion.

    b. Part 2: All participants must have at least 1 measurable lesion as defined by RECIST v1.1 or RANO (for CNS tumors). For Participants with DMG-H3K27a or PDGFRA and/or KIT mutant/amplified solid tumors, including CNS tumors that have progressed despite prior therapy, who have received radiation therapy, at least 1 measurable lesion must not have been irradiated, or must have clearly progressed since being irradiated as per RANO and must be ≥ 12 weeks from radiation to any target lesion. For up to 5 Participants with newly diagnosed DMG-H3K27a where there is no standard therapy that may convey clinical benefit exists as judged by the investigator, progression of disease of a measurable lesion after irradiation is not required.

  5. A Lansky (\< 16 years of age) or (≥ 16 years of age) score of at least 50. If the Participant is unable to walk due to paralysis, but is mobile in a wheelchair, the participant is considered ambulatory for the purpose of assessing their performance status.
  6. Participant agrees to utilize consistent with local regulations.

    • Male participants: Are vasectomized, or agree to use condoms, as defined in Section 5.4.2, from the start of Screening until 6 weeks after the last dose of study treatment, or practice true abstinence (when this is in line with the preferred and usual lifestyle of the Participant, see Section 5.4.2), or have a female partner who is NOT of .
    • Female participants: Agree to use effective contraception, as defined in Section 5.4.2, from the start of Screening until 6 weeks after the last dose of study treatment and have a male partner who uses a condom, or practice true abstinence (when this is in line with the preferred and usual lifestyle of the Participant), or have a male partner who is vasectomized with confirmed azoospermia.
  7. Participant can give written informed consent/assent before any study-specific Screening procedures (if feasible). Parental/legal guardian consent will be determined by local, regional, and/or national guidelines.

Exclusion criteria

Exclusion Criteria

  1. Participant has any of the following within 14 days before the first dose of study treatment:

    1. count \< 75 × 10\^9/L (\< 100 × 10\^9/L if a CNS tumor) with no platelet transfusion within 14 days prior to the measurement.
    2. (ANC) \< 1.0 × 10\^9/L.
    3. \< 8.0 g/dL with no RBC transfusion ≤ 7 days prior to the measurement.
    4. or ALT > 3 × the for age; except in Participants with tumor involvement of the liver who must not have AST and ALT > 5 × ULN for age.
    5. Total > 1.5 × ULN for age; and in presence of Gilbert's syndrome, total bilirubin > 3 × ULN or direct bilirubin > 1.5 × ULN.
    6. Serum creatinine > 1.5 × ULN for age.
    7. or prothrombin time (PT) > ULN (> 1.5 × ULN if on prophylactic reversible anticoagulants).
  2. Participant has a > 470 msec. Participant has a familial or personal history of prolonged QT syndrome or Torsades de pointes.
  3. Participant has , uncontrolled cardiovascular disease including congestive heart failure Grade III or IV according to the classification; myocardial infarction or unstable angina within the previous 6 months, uncontrolled hypertension (> 95th percentile for age), or clinically significant, uncontrolled arrhythmias, including bradyarrhythmias that may cause QT prolongation (eg, Type II second-degree heart block or third-degree heart block).
  4. Participant received the following systemic antineoplastic therapies:

    1. Temozolomide within 4 weeks prior to the first dose of study drug
    2. Nitrosurea within 6 weeks prior to the first dose of study drug
    3. Any other systemic antineoplastic therapy (including experimental therapy) within 5 half-lives or 28 days prior to the first dose of study drug, whichever is shorter.
    4. Focal external beam radiotherapy, including stereotactic radiosurgery, within 6 weeks prior to the first dose of avapritinib to either target or nontarget lesions. Systemic radiopharmaceuticals, including nonstereotactic radiosurgery, within 2 weeks of the first dose of avapritinib (within 6 weeks for Participants with CNS tumors). Craniospinal irradiation within 6 weeks prior to the first dose of avapritinib.
    5. All AEs related to other antineoplastic therapies (eg, systemic antineoplastics, radiotherapy) must have resolved to Grade ≤ 1 (Grade ≤ 2 for peripheral neuropathy and/or ototoxicity) prior to the first dose of avapritinib.
  5. Participant has previously received treatment with avapritinib.
  6. Participant received stem cell transplant following myeloablative therapy or chimeric antigen receptor T cell therapy within 3 months prior to the first dose of avapritinib or prior allogeneic stem cell transplant within 1 year and no evidence of Grade 1 or greater and no for graft-versus-host disease ( for primary being permitted). Participants who received stem cell reinfusion following nonmyeloablative therapy are eligible once they meet the peripheral blood count criteria in Exclusion Criterion #1.
  7. Participant requires ongoing treatment or has received treatment within 28 days before the start of avapritinib administration with drugs or foods that are strong inhibitors or inducers.
  8. Participant has had a major surgical procedure within 14 days of the first dose of study treatment (procedures such as central venous catheter placement, tumor needle , and feeding tube placement are not considered major surgical procedures).
  9. Participant has a history of another primary malignancy that has been diagnosed or required therapy within 3 years before the first dose of avapritinib. The following prior malignancies are not exclusionary: completely resected basal cell and squamous cell skin cancer, curatively treated localized prostate cancer, and completely resected carcinoma in situ of any site.
  10. Female subjects of who are unwilling, if not or surgically sterile, to abstain from sexual intercourse or employ highly effective from the time of and for at least 6 weeks after the last dose of study treatment. Male subjects who are unwilling, if not surgically sterile, to abstain from sexual intercourse or employ highly effective contraception from the time of informed consent and for at least 6 weeks after the last dose of study treatment.
  11. Participant is pregnant, as documented by a serum β-hCG pregnancy test consistent with pregnancy obtained at Screening and within 72 hours before the first dose of study treatment. Participants with β-hCG values that are within the range for pregnancy but are not pregnant (false-positives) may be enrolled with written consent of the Sponsor after pregnancy has been ruled out. Female subjects of nonchildbearing potential (premenarchal, bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) do not require a serum β-hCG test.
  12. Participant is breastfeeding.
  13. Participant has prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the Investigator's opinion, could affect the safety of the Participant; alter the absorption, distribution, metabolism, or excretion of the study drug; or impair the assessment of study results.
  14. History of thrombosis requiring treatment within the past 6 months. This exclusion does not apply to catheter-related thrombosis if the catheter has been removed and did not require any other treatment in the previous 3 months.
  15. Participants who require anticoagulants, with the exception of stable doses of prophylactic reversible anticoagulants.
  16. Participants who are unable to swallow tablets (in Part 1) or minitablets (in Part 2) within the sprinkle capsules.
  17. Participants with a known risk of intracranial bleeding, such as a brain aneurysm that has not been removed or repaired, or a history of intracranial bleeding within the past year, or radiographic evidence of hemorrhage on Screening MRI. Exceptions are: Participants with primary CNS tumors (provided they have not had CNS bleeding within 2 weeks of the first dose of avapritinib) or Participants with punctate hemorrhages \< 3 mm.
  18. History of a seizure disorder that is not well controlled on current antiepileptic medications.
  19. Participant is unwilling or unable to comply with scheduled visits, treatment administration plan, laboratory tests, or other study procedures and study restrictions.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    avapritinib

    Avapritinib tablets for oral administration. Avapritinib will be dosed daily for 28 day cycles.

    Drug: avapritinib

Interventions

  • oral administration

    Also known as: BLU-285

06

What researchers measure

Primary outcomes

  1. Determination of recommended Part 2 dose (Part 1)

    Time frame: up to 8 months

  2. Objective Response Rate (Part 2)

    Time frame: up to 36 months

  3. Rate and severity of adverse events (Part 1)

    Time frame: up to 8 months

Secondary outcomes

  1. Objective Response Rate (Part 1 and Part 2)

    Time frame: up to 42 months

  2. Rate and severity of adverse events (Part 1 and Part 2)

    Time frame: up to 42 months

  3. Palatability assessments as measured by the 5-point Hedonic scale (Part 1 and Part 2)

    Time frame: up to 42 months

  4. Duration of Response (Part 1 and Part 2)

    Time frame: up to 42 months

  5. Progression-free survival (Part 1 and Part 2)

    Time frame: up to 42 months

  6. Disease control rate (Part 1 and Part 2)

    Time frame: up to 42 months

  7. Time to response (Part 1 and Part 2)

    Time frame: up to 42 months

  8. Cmax (Part 1 and Part 2)

    Time frame: up to 36 months

  9. AUC(0-24) (Part 1 and Part 2)

    Time frame: up to 36 months

  10. Tmax (Part 1)

    Time frame: up to 36 months

  11. T 1/2 (Part 1)

    Time frame: up to 36 months

  12. Ctrough (Part 2)

    Time frame: up to 36 months

  13. Change from baseline in levels of KIT and PDGFRA mutant allele fractions in peripheral blood (Part 1 and Part 2)

    Time frame: up to 42 months

07

Study locations

26 sites
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • University of California San Francisco, Benioff Children's Hospital
    San Francisco, California 94518, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Ann and Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • The Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • UPMC Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • Children's Medical Center
    Dallas, Texas 75235, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Sydney Children's Hospital, Kids Cancer Center
    Sydney, New South Wales 2031, Australia
  • Royal Children's Hospital
    Parkville, Victoria 3052, Australia
  • Medizinische Universitat Wein
    Vienna, State of Vienna 1090, Austria
  • The Hospital for Sick Children
    Toronto, Ontario M5G1X8, Canada
  • Gustave Roussy
    Villejuif, 94805, France
  • Universitaetsmedizin Göttingen
    Göttingen, Lower Saxony 37075, Germany
  • Hopp Children's Cancer Center
    Heidelberg, Germany
  • Dipartimento di Oncologia Medica ed Ematologia - S.C. Pediatria Oncologica
    Milan, 20133, Italy
  • Asan Medical Center
    Seoul, 05505, South Korea
  • Samsung Medial Center
    Seoul, 06351, South Korea
  • Great Ormond Street Hospital For Children
    London, WC1N 3JH, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Nov 2025, 44 months.

Of 35 phase 1/2 interventional studies under Central Nervous System Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 85. This study's 44 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2021
First posted
Feb 26, 2021
StartActual
Feb 24, 2022
Primary completionActual
Nov 21, 2025
CompletionActual
Nov 21, 2025
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04773782
Responsible party
Sponsor
First posted
Feb 26, 2021
Start date
Feb 24, 2022
Primary completion
Nov 21, 2025
Completion
Nov 21, 2025
Last update
Jan 13, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avapritinib

Start the discussion